In two separate pieces of final and binding guidance, NICE has recommended Bayer's Eylea (aflibercept) and Allergan's Ozurdex (dexamethasone intravitreal implant) for treating NHS patients with diabetic macular edema. Both sets of recommendations come with restrictions: Eylea can be used if the eye has a central retinal thickness of 400 micrometres or more at the start of treatment, and if Bayer provides the drug at a discount as agreed in a confidential patient access scheme. Meanwhile, Ozurdex is to be used in patients if the implant is to be used in an eye with an intraocular (pseudophakic) lens and if non-corticosteroid treatment is unsuitable or ineffective. Both drugs will compete against Roche's Lucentis (ranibizumab) and off-label Avastin. NICE first put its guidance out for consultation in February.
NICE says why eye to Ozdurex and Eylea for DME
In two separate pieces of final and binding guidance, NICE has recommended Bayer's Eylea (aflibercept) and Allergan's Ozurdex (dexamethasone intravitreal implant) for treating NHS patients with diabetic macular edema. Both sets of recommendations come with restrictions: Eylea can be used if the eye has a central retinal thickness of 400 micrometres or more at the start of treatment, and if Bayer provides the drug at a discount as agreed in a confidential patient access scheme. Meanwhile, Ozurdex is to be used in patients if the implant is to be used in an eye with an intraocular (pseudophakic) lens and if non-corticosteroid treatment is unsuitable or ineffective. Both drugs will compete against Roche's Lucentis (ranibizumab) and off-label Avastin. NICE first put its guidance out for consultation in February.
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
More from Scrip
Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.
The Belgian drugmaker is boosting its biologics capacity over the pond.
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.